| Customization: | Available |
|---|---|
| Powder: | Yes |
| Customized: | Customized |
|
Still deciding? Get samples of $ !
Request Sample
|
Suppliers with verified business licenses
Audited Supplier Audited by an independent third-party inspection agency
| Product Name | Lorlatinib |
| Appearance | White Powder |
| CAS No. | 1454846-35-5 |
| MF | C21H19FN6O2 |
It is mainly targeted at patients with non-small cell lung cancer who are resistant to the first-generation ALK inhibitors crizotinib and resistant to the second-generation ALK inhibitors Ceritinib and Alectinib.
Laroratinib (PF-06463922) is an ALK inhibitor modified from Crizotinib, which entered clinical trials in 2014 for the treatment of Chemicalbook lung cancer.It is mainly targeted at patients with non-small cell lung cancer who are resistant to the first-generation ALK inhibitors crizotinib and resistant to the second-generation ALK inhibitors Ceritinib and Alectinib.
){kind=link}